Literature DB >> 26284445

Therapy: Risk of metformin use in patients with T2DM and advanced CKD.

Guntram Schernthaner1, Marie Helene Schernthaner-Reiter2.   

Abstract

In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26284445     DOI： 10.1038/nrendo.2015.132

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  9 in total

1.  Metformin use and mortality among patients with diabetes and atherothrombosis.

Authors:  Ronan Roussel; Florence Travert; Blandine Pasquet; Peter W F Wilson; Sidney C Smith; Shinya Goto; Philippe Ravaud; Michel Marre; Avi Porath; Deepak L Bhatt; P Gabriel Steg
Journal:  Arch Intern Med       Date:  2010-11-22

2.  Using metformin in the presence of renal disease.

Authors:  Tahseen A Chowdhury; Roisin Wright; M Magdi Yaqoob
Journal:  BMJ       Date:  2015-04-14

3.  Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?

Authors:  Robert C Stanton
Journal:  Am J Kidney Dis       Date:  2015-05-08       Impact factor: 8.860

Review 4.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

5.  The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.

Authors:  Janna K Duong; Timothy J Furlong; Darren M Roberts; Garry G Graham; Jerry R Greenfield; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

6.  Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.

Authors:  Szu-Chun Hung; Yu-Kang Chang; Jia-Sin Liu; Ko-Lin Kuo; Yu-Hsin Chen; Chih-Cheng Hsu; Der-Cherng Tarng
Journal:  Lancet Diabetes Endocrinol       Date:  2015-06-17       Impact factor: 32.069

Review 7.  Metformin and other antidiabetic agents in renal failure patients.

Authors:  Jean-Daniel Lalau; Paul Arnouts; Adnan Sharif; Marc E De Broe
Journal:  Kidney Int       Date:  2014-03-05       Impact factor: 10.612

8.  How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.

Authors:  Alfred Penfornis; Jean Frédéric Blicklé; Béatrice Fiquet; Stéphane Quéré; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2014-06-13

9.  Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Linus Schiöler; Ann-Marie Svensson; Katarina Eeg-Olofsson; Junmei Miao Jonasson; Björn Zethelius; Jan Cederholm; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2012-07-13       Impact factor: 2.692
  9 in total
  3 in total

Review 1.  Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist.

Authors:  Filippo Mariano; Luigi Biancone
Journal:  J Nephrol       Date:  2020-12-29       Impact factor: 3.902

Review 2.  Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.

Authors:  G Schernthaner; G-H Schernthaner
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

Review 3.  Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies.

Authors:  Guntram Schernthaner; Marie Helene Schernthaner-Reiter
Journal:  Diabetologia       Date:  2018-02-07       Impact factor: 10.122
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.